Status:
UNKNOWN
Study of Subcutaneous Versus Intravenous Administration of Bortezomib in Patients With Multiple Myeloma in China
Lead Sponsor:
The First Affiliated Hospital of Soochow University
Conditions:
Multiple Myeloma Proved by Laboratory Tests
Eligibility:
All Genders
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
Intravenous injection is the standard administration route of bortezomib; however, subcutaneous administration is an important alternative. We want to compared the pharmacokinetic of subcutaneous vers...
Detailed Description
The new diagnosed multiple myeloma patients are randomized to receive bortezomib by standard intravenous bolus (n=10) or subcutaneous injection (n=10) at the recommended dose and schedule (1.3 mg/m2),...
Eligibility Criteria
Inclusion
- Must be Multiple Myeloma Proved by Laboratory Tests
- Must have the ability to observe the efficacy and events
- Patient must have the ability to understand and willingness to provide written informed consent in the study and any related procedures being performed
Exclusion
- If have uncontrolled intercurrent illness including ongoing or active infection,heart failure,unstable angina pectoris,or psychiatric illness/social situations that study requirements
- If have severe side-effects on bortezomib
Key Trial Info
Start Date :
May 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2017
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT01812096
Start Date
May 1 2014
End Date
June 1 2017
Last Update
August 18 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The First Affiliated Hospital of Soochow University
Suzhou, Jiangsu, China, 215006